SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis

SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis

FXR agonists have been investigated for the treatment of non-alcoholic steatohepatitis and liver fibrosis but the clinical efficacy is not optimal. Here the authors show that enhanced FXR SUMOylation in activated hepatic stellate cells reduces FXR signaling and that this can be rescued by SUMOylatio...

Full description

Bibliographic Details
Main Authors: Jiyu Zhou, Shuang Cui, Qingxian He, Yitong Guo, Xiaojie Pan, Pengfei Zhang, Ningning Huang, Chaoliang Ge, Guangji Wang, Frank J. Gonzalez, Hong Wang, Haiping Hao
Format: Article
Language:English
Published: Nature Portfolio 2020-01-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-019-14138-6

Internet

https://doi.org/10.1038/s41467-019-14138-6

Similar Items